Morbidity and Mortality Weekly Report: Recommendations and Reports, June 25, 1993 / Vol. 42 / No. RR-9

Details

• Alternative Title:
  Recommendations for Counseling Persons Infected with Human T-Lymphotrophic Virus, Types I and II ; Recommendations on Prophylaxis and Therapy for Disseminated Mycobacterium avium Complex for Adults and Adolescents Infected with Human Immunodeficiency Virus
• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR): Recommendations and Reports
• Personal Author:
  Khabbaz, Rima F. ; Fukuda, Keiji ; Kaplan, Jonathan E. ; Bianco, Cielso ; Blattner, William A. ; Busch, Michael ; Dodd, Roger ; Epstein, Jay ; Gilcher, Ronald ; Jackson, Craig ; Katz, Louis ; Kleinman, Steven ; Murphy, Edward L. ; Nemo, George ; Poiesz, Bernard J.
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.) ; U.S. Public Health Service Working Group for Recommendations for Counseling Persons Infected with Human T-Lymphotropic Virus, Types I and II.
• Description:
  This issue contains two articles with recommendations on counseling and prophylaxis and therapy for Human T-Lymphotrophic Virus and Disseminated Mycobacterium avium Complex for individuals infected with HIV.
  
  The human T-lymphotropic viruses, type I (HTLV-I) and type II (HTLV-II), are closely related but distinct retroviruses that can infect humans. They are different from the human immunodeficiency viruses that cause acquired immunodeficiency syndrome. Screening of the U.S. blood supply for HTLV-I/II, which began in 1988, identifies HTLV-I-and HTLV-II-infected persons who should be counseled regarding their infections. This document summarizes current information about HTLV, types I and II, and presents recommendations developed by CDC and a U.S. Public Health Service working group for counseling HTLV-I and HTLV-II-infected persons.
  
  Mycobacterium avium complex (MAC) causes disseminated disease in up to 40% of patients with advanced human immunodeficiency virus (HIV) disease in the United States. A U.S. Public Health Service Task Force convened to address the prophylaxis and therapy of MAC recommends that patients with HIV infection and <100 CD4+ T-lymphocytes/μL be administered prophylaxis against MAC. The recommended regimen is rifa butin, 300 mg by mouth daily, for the patient's lifetime. If disseminated MAC develops, a treatment regimen containing clarithromycin or azithromycin and at least one other agent is recommended. Diagnosis, therapy, and prophylaxis for HIV-infected children follow similar guidelines.
  
  
• Subjects:
  AIDS-Related Opportunistic Infections / Prevention & Control Anti-Bacterial Agents / Therapeutic Use HIV Infections / Complications HTLV-II Infections HTLV-I Infections Humans Mycobacterium Avium-intracellulare Infection / Complications Mycobacterium Avium-intracellulare Infection / Prevention & Control Patient Education As Topic Rifamycins / Therapeutic Use United States Public Health Service

  More +
• Source:
  Morbidity and Mortality Weekly Report (MMWR): Recommendations and Reports, 1993; v. 42, no. 9
• Series:
  Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  1057-5987 (print)
• Pubmed ID:
  8393133
• Document Type:
  Journal Issue
• Genre:
  Practice Guideline
• Place as Subject:
  United States
• Pages in Document:
  28 pdf pages
• Volume:
  42
• Issue:
  9
• Peer Reviewed:
  Yes
• Collection(s):
  Guidelines and Recommendations Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:4d8f99a6cfc11d3d604f527ecbb603b38513c8187eea269776bf8a3a2880210ce5d7cf3104aedb4d494d391f5023227723f35d8fe987b771a397bb5beb1461c4
• Download URL:
  https://stacks.cdc.gov/view/cdc/7366/cdc_7366_DS1.pdf
• File Type:
  [PDF - 225.77 KB ]